Current and future role of fedratinib in the treatment of myelofibrosis.
Sign Up to like & getrecommendations! Published in 2020 at "Future oncology"
DOI: 10.2217/fon-2019-0612
Abstract: Fedratinib (INREBIC® [fedratinib] capsules, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation), is a potent JAK2 inhibitor that has been approved for use in myelofibrosis, both as a first-line agent and also in… read more here.
Keywords: fedratinib; current future; myelofibrosis; role fedratinib ... See more keywords